Otterbein University

Digital Commons @ Otterbein
Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

2022

Perioperative Malignant Hyperthermia
Mitchell McCorkle
mccorkle2@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn
Part of the Perioperative, Operating Room and Surgical Nursing Commons

Recommended Citation
McCorkle, Mitchell, "Perioperative Malignant Hyperthermia" (2022). Nursing Student Class Projects
(Formerly MSN). 500.
https://digitalcommons.otterbein.edu/stu_msn/500

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an
authorized administrator of Digital Commons @ Otterbein. For more information, please contact
digitalcommons07@otterbein.edu.

Perioperative Malignant Hyperthermia
Mitchell McCorkle, BSN, RN, CCRN
Otterbein University, Westerville, Ohio
Subject
Malignant Hyperthermia (MH)
● Malignant Hyperthermia is, “a
biochemical chain reaction response
“triggered” by commonly used general
anesthetics and the paralyzing agent
succinylcholine (a neuromuscular
blocker), within the skeletal muscles of
susceptible individuals” (Malignant
Hyperthermia Association of the United
States, n.d.)
● Incidence of MH
○ The exact incidence is difficult to
appraise due to the infrequency
and possible misdiagnosis of
events.
○ An estimated incidence is listed
from 1:10,000 to 1:220,000 in
past reports (In, Ahn, Lee, &
Kang, 2017).

Significance
● Although Malignant Hyperthermia is
most commonly known as an adverse
surgical event, it can also be caused
by stress, heatstroke and strenuous
exercise (Bin, Wang, and Tang, 2022).
● In the United States, there are
approximately 60,000 patients that
undergo a surgical procedure with
general anesthesia (National
Institute of Health, 2019).
● General anesthesia
○ General anesthesia is inducing a
state of unconsciousness and
inability to perceive pain while
controlling the autonomic
responses (Smith, D’Cruz,
Rondeau, & Goldman, 2021)
○ Common general anesthetics
that may cause perioperative
Malignant Hyperthermia are
divided into two categories of
volatile inhaled anesthetics and
depolarizing neuromuscular
blocking agents.
● Malignant Hyperthermia was
selected for this project because
although it is rare, this is a very
severe and even deadly risk of
surgery. It is the responsibility of the
anesthesia provider to monitor and
rapidly treat this condition.
● Further education on the severity
and importance of MH awareness can
decrease incidence of morbidity and
mortality with this condition.

Pathophysiological Processes
Normal Physiology
● Normal skeletal muscle contraction
○ Nerve impulse propagates to the
nerve terminal activating the
voltage gated calcium channels
(Mullins, 2018).
○ Increased calcium in the
cytoplasm triggers
acetylcholine(ACh) release via
exocytosis form the storage
vesicles (Mullins, 2018).
○ ACh binds to nicotinic ACh
receptors of the postsynaptic
membrane activating voltage
gated ion channels (Mullins,
2018)
○ Influx of positive ions allows the
sarcolemma to reach threshold
and depolarize (Mullins, 2018)
○ Depolarization activates
voltage-gated sodium ion
channels that propagate the
impulse into muscle tissue
(Mullins, 2018).
○ The impulse then activates L-type
calcium voltage-gated ion
channels in the transverse tubules
(t-tubules) (Mullins, 2018).
○ Activation of the L-type calcium
channels causes a conformational
change (Mullins, 2018).
○ The conformational change
activates the DHPR which is
linked to the RYR1 receptor
causing a chain activation
(Mullins, 2018).
○ Once the RyR1 receptor is
activated, calcium is released
from the sarcoplasmic reticulum
causing muscle contraction
(Mullins, 2018).

Underlying
Pathophysiology
● Results due to an autosomal dominant
mutation on the ryanodine receptor
(type 1: RyR1), dihydropyridine
receptor (DHPR) (Mullins, 2018).
● The mutation causes an abnormal
intensified release of calcium from the
sarcoplasmic reticulum in skeletal
muscle cells (Mullins, 2018)
● Hypermetabolism of the skeletal
muscles results due to the excess
calcium release from the sarcoplasmic
reticulum (Mullins, 2018)
● Prolonged contraction causes
hypermetabolism and inhibited
relaxation cause skeletal muscle tissue
to consume immense amounts of
adenosine triphosphate (ATP) which
supplies energy to cells (Gregory &
Weant, 2021).
● Hyperthermia is produced by the
unrelenting contraction and
continuous metabolic processes
(Gregory & Weant, 2021).
● Once the ATP stores are depleted, the
body begins to compensate by
entering anaerobic metabolism to
produce more ATP and therefore
begins producing lactate or lactic acid
(Gregory & Weant, 2021).
● All of the hypermetabolic processes
can lead to cell injury and destruction
releasing creatinine kinase (CK) and
potassium to the extracellular space
(Gregory & Weant, 2021).
● Hyperkalemia from cell destruction
can lead to detrimental cardiac
arrhythmias (Gregory & Weant, 2021).
● Together, these metabolic
disturbances can lead to patient
mortality.

Triggering
Agents
● Volatile Anesthetics
○ Desflurane
○ Enflurane
○ Isoflurane
○ Halothane
○ Sevoflurane (Gregory & Weant,
2021)
● Depolarizing Neuromuscular Blocker
○ Succinylcholine (Anectine) (Gregory
& Weant, 2021)
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Signs & Symptoms
● Early signs and symptoms of malignant
hyperthermia
○ Unexplained rise in end-tidal
Carbon Dioxide (ETCO2) is usually
the first sign
○ Tachycardia
○ Dysrhythmias
○ Abrupt increase in core body
temperature. The rate of
temperature increase is more
important than the temperature
peak.
○ Generalized skeletal muscle rigidity
○ Rhabdomyolysis (Smith, Tranovich,
& Ebraheim, 2018).
● Late signs and symptoms of malignant
hyperthermia
○ Respiratory acidosis
○ Metabolic acidosis
○ Increases in serum potassium
○ Elevation of creatinine kinase (CK)
○ Myoglobinuria (Smith et al., 2018).

Significance of Pathological Processes
● In comparison to the total amount of surgeries that take place all around the world, the
incidence of Malignant Hyperthermia is relatively low. Although the incidence is low,
there should be precautions taken to ensure the utmost patient safety when exposed
to triggering agents. Anesthesia providers should understand the severity of Malignant
Hyperthermia, be able to identify signs and symptoms while promptly treating with
the supplies available.
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(University of Florida Department of Anesthesiology, n.d.)

Diagnosis
● There are four components leading to a
Malignant Hyperthermia diagnosis:
clinical presentation, family or medical
history, in-vitro caffeine-halothane
contracture testing, and genetic testing
(Bin, Wang, and Tang, 2022).
● Two types of testing give a definitive
diagnosis of Malignant Hyperthermia
susceptibility: genetic testing and
muscle biopsy (Malignant
Hyperthermia Association of the United
States, n.d.)
● The diagnosis gold standard is in vitro
caffeine-halothane contracture testing
(Bin, Wang, and Tang, 2022).
● Caffeine-Halothane Contracture testing
must take place in specific labs and
there are only four in the United States
(Gregory & Weant, 2021).
● It is not suggested to test every surgical
patient for the mutation that causes
Malignant Hyperthermia (Gregory &
Weant, 2021).
● One or simultaneous occurrences of the
following manifestations may indicate
the onset of Malignant Hyperthermia
and lead to further testing:
○ Muscular spasm or rigidity
(localized or diffuse)
○ Unexplained tachycardia or
arrhythmias
○ Body temperature that rises 1-2
degrees celsius over 5-15 minutes
○ Circulatory and Respiratory failure
leading to arrhythmia, cyanosis, and
oliguria (Bin, Wang, and Tang,
2022)..

Treatment
● The initial and possibly most
important step to treat and episode of
Malignant Hyperthermia is the
removal of the causative agent
(Gregory & Weant, 2021).
● If succinylcholine is used and more
paralytics are needed, a
non-depolarizing neuromuscular
blocker such as rocuronium or
vecuronium are indicated (Gregory &
Weant, 2021).
● The anesthesia provider should
increase the fraction of inspired
oxygen to 100% and then
hyperventilate the patient to eliminate
excess carbon dioxide (Gregory &
Weant, 2021).
● If accessible, activated charcoal filters
should be added to the inspiratory and
expiratory arms of the respiratory
circuit (Gregory & Weant, 2021)..

Treatment
Continued
● The drug of choice for Malignant
Hyperthermia treatment is Dantrolene
and it should be used as soon as
possible (Gregory & Weant, 2021).
● Dantrolene impedes calcium ion release
from the sarcoplasmic reticulum and
therefore interferes with skeletal
muscle contraction (Gregory & Weant,
2021).
● Dantrolene is used in an acute
Malignant Hyperthermia crisis but can
also be used in prophylaxis of
Malignant Hyperthermia (Gregory &
Weant, 2021).
● The prophylactic Dantrolene dose is 2.5
milligrams per kilogram (mg/kg)
administered one hour and 15 minutes
prior to surgery (Gregory & Weant,
2021).
● In an acute Malignant Hyperthermia
crisis the Dantrolene dose is also
2.5mg/kg but is given every 10 to 15
minutes until symptoms recede
(Gregory & Weant, 2021).
● Once the symptoms have subsided, it is
recommended to give 1mg/kg every
four to six hours or 0.25mg/kg in a
continuous infusion for a minimum of
24 hours (Gregory & Weant, 2021).
● However, Dantrolene is not available in
all countries (Gong, 2021)
● When Dantrolene is not available,
diagnosis, early warning and immediate
effective interventions are needed
(Gong, 2021)

Conclusion
● Malignant Hyperthermia is a rare
possibly fatal ailment that requires
prompt intervention.
● Malignant Hyperthermia is
inconsistent in it manifestations
(Mullins, 2018).
● Dantrolene has shown to be very
effective in the treatment of Malignant
Hyperthermia (Gregory & Weant,
2021).
● Stocking Dantrolene is highly
recommended wherever the
depolarizing neuromuscular blocker
succinylcholine is used (Larach, 2019).
● Without Dantrolene, extreme vigilance
is needed to treat the manifestations to
prevent mortality (Gong, 2021)
● Drills simulating a Malignant
Hyperthermic crisis are suggested to
practice the immediate response
needed during these situations
(Gregory & Weant, 2021).
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Implications for
Nursing Care
● The entire perioperative team including
anesthesia and PACU should be aware
of the signs and symptoms of Malignant
Hyperthermia.
● Malignant Hyperthermia can present
during general anesthesia or in the
early post-operative stage (Mullins,
2018)
● Prompt treatment is necessary to
prevent the detrimental effects of
Malignant Hyperthermia (Gregory &
Weant, 2021).
● Further education for both anesthesia
and nursing staff can increase
awareness of MH and decrease patient
mortality.
● Simulation of Malignant Hyperthermia
situations have shown beneficial
outcomes in training perioperative staff
(Schaad, 2017).
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